Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. - Wikidata - wikimedia - TriplyDB

Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.

Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.

http://www.wikidata.org/entity/Q46599371

about

Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics PPARs and the cardiovascular system Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis PPARs: Protectors or Opponents of Myocardial Function?The endocrine function of adipose tissue: an update Soluble epoxide hydrolase in atherosclerosis Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation Essential role of PKC-zeta in normal and angiotensin II-accelerated neointimal growth after vascular injury Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice.Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.DJ-1 contributes to adipogenesis and obesity-induced inflammation.Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction.β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction Adipokines: molecular links between obesity and atheroslcerosis.Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation.Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse.Animal models of cardiovascular diseases The pathophysiology of obesity and its clinical manifestations.Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats.Epigallocatechin-3-gallate Regulates Inducible Nitric Oxide Synthase Expression in Human Umbilical Vein Endothelial Cells Differential roles of endothelin-1 in angiotensin II-induced atherosclerosis and aortic aneurysms in apolipoprotein E-null mice.Vascular inflammation and endothelial dysfunction in experimental hypertension.Transcriptional profiling and network analysis of the murine angiotensin II-induced abdominal aortic aneurysm.Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes Transcriptome Profiling and Molecular Pathway Analysis of Genes in Association with Salinity Adaptation in Nile Tilapia Oreochromis niloticus.Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension.The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance The role of estrogen on the pathology of cerebral aneurysms.Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways.Enhancement of Adipocyte Browning by Angiotensin II Type 1 Receptor Blockade.Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.Is atrial fibrillation an inflammatory disorder?Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.Differential metabolic actions of specific statins: clinical and therapeutic considerations Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

P2860

Q24608652-086B1B97-84C5-442A-8A88-A06BCE54B469 Q24642728-5F09A899-A799-41DA-9BD6-7504DD7FCA2E Q24657323-DB8092EF-2ABB-492B-A317-E9CA90D4F834 Q26771753-BC5F8A71-726B-4E4C-AD10-194EFB317D88 Q28305131-C2716248-E3A0-4711-8E08-10600C09D18A Q28395004-CD5906A8-1782-47B3-A170-86BAAD637F83 Q28485173-CD57ACFA-226F-4B58-A902-6F9F283076F7 Q28579623-2691F8EC-D673-4CDD-8891-3241831B263F Q30528431-40BC3FF8-5B77-4F61-91EA-2DE75D0D6133 Q33166521-625DBB9B-9906-4D90-8733-A606EE00F50B Q33585657-5A72E4B8-AE47-4F25-84B7-0004C16680EC Q33749501-F424CAAC-078A-4776-BE16-2B4E71F6BC19 Q33817996-95349A0E-E99A-4D64-9E46-7537FE7B0954 Q33985855-A291229A-8F48-46E0-A472-6B98217008BE Q34046462-28EB22DA-E40A-48DA-9849-07C37839D02F Q34231611-CCB49B3E-BF68-455F-8564-4DF7EF5EBCA4 Q34384883-8A308842-866D-4D58-AB61-914FCFD76357 Q34521265-D371BDB5-F8D6-4BE2-AE6F-0C3DAAAB4D76 Q34550560-45218132-97B7-4A60-AFF0-F8C71B368737 Q34591282-78DCEB80-CC02-434D-B638-599EDC897E89 Q35013868-A3300FC4-87E7-4AD3-9A04-04BDFEDC706B Q35085406-A1BE14AC-C2DC-4ACA-A0E3-30909E1A3343 Q35134981-F41701AC-B5C3-46EE-808D-0B5E542F68A6 Q35168157-0CB6BF74-1D4C-4E3C-B59A-23245D44AA97 Q35207893-10147FF1-3498-4800-BA28-F89197B51815 Q35233864-92C1063C-EC2E-4336-8C08-83303C3206C7 Q35612987-B87C76A6-9FD1-4379-8F33-8BC1A76496AD Q35754749-F26E6394-AB26-4C94-B2B9-FF869CBBE465 Q35819219-A6319055-7DED-40EE-8128-5758DE98FE0B Q35841988-CB103E2E-F370-43B4-8C26-13460DEEDEE4 Q35847323-1A0BEECA-92C5-4764-AC8B-3BE5478DEBA0 Q35855689-EDFAC824-7AC1-44E3-B59A-182F6BDED6D7 Q36017502-F0EE4C7F-F7AA-4C75-993D-FD6085237644 Q36136825-7661CFD7-C80D-404D-81EF-51C3646AAA41 Q36228066-D9A93416-C11A-4562-9F01-C6F40AF77EBA Q36257966-162102AF-E335-4429-B435-13F85EEFBBF0 Q36309624-0668D3F4-F9C5-4456-9108-AAECC1502195 Q36401585-EE102F0D-23F6-4B27-A253-FB663C0941F5 Q36406951-379100BB-01CF-4E2A-A7FE-BC51636C8932 Q36410269-DB16960A-AFD6-4FB1-A75A-AA0944830241

P2860

Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.

http://www.wikidata.org/entity/Q46599371

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Angiotensin II is associated w ...... s and downregulation of PPARs.

@en

Angiotensin II is associated w ...... s and downregulation of PPARs.

@nl

type

label

Angiotensin II is associated w ...... s and downregulation of PPARs.

@en

Angiotensin II is associated w ...... s and downregulation of PPARs.

@nl

prefLabel

Angiotensin II is associated w ...... s and downregulation of PPARs.

@en

Angiotensin II is associated w ...... s and downregulation of PPARs.

@nl

P1433

Q46599371-DBF6D30C-6991-460E-B6CD-FE2845DFE290

P1476

Q46599371-6E54E21B-82D2-415F-B4EA-B8FAECE9EEEE

P2093

Q46599371-19159E46-D0E0-40DE-A64A-6688A2197A69

Q46599371-1BF9DA22-D62D-4B6E-95EF-DE6369102202

Q46599371-24659812-B2B4-4A15-A2AF-A3BB5182376F

Q46599371-26E05CCB-4F63-46D2-A64E-DA8D0B44BBE5

Q46599371-58B43701-4890-4BD5-8C95-21E9761204DD

Q46599371-5EAAB385-C9C5-4B0B-89D1-C18A1314798D

Q46599371-9CBF4542-CD5A-447B-86A9-822C6DB9EDCD

Q46599371-C1DA089A-B18A-4F90-B34C-1FD5FAF6DFE5

P2860

Q46599371-0F394D38-8516-4188-8E95-B8FEDA2AA184

Q46599371-10485868-9B7D-44DE-A20F-5538099A1A35

Q46599371-120EDAD8-EFC7-4F14-AD07-3588647A1908

Q46599371-12681118-B3E4-402F-BB3A-EC630B683402

Q46599371-1B302281-F518-41B6-89E5-9C4E17321934

Q46599371-21891498-A531-44B8-B248-DD73FE5C6E63

Q46599371-2AFBE321-CD3C-45FD-9754-C319C7A28928

Q46599371-38711C4D-A84E-4289-B73B-02320D732BD1

Q46599371-3D273E0C-FDC7-4704-A99D-2B7A96CC91C6

Q46599371-6EB61470-5EB8-4D6B-84E0-FC5FA42C8E43

P304

Q46599371-D149B5CD-CF53-4039-8796-3ED7D08BAE6A

P31

Q46599371-5598966D-6828-49DE-B244-C9BD9CC6F70B

P356

Q46599371-062F1A4F-7395-41E9-88D2-0C46084B5833

P433

Q46599371-5AA59427-04E9-4E44-A180-225AFC56797D

P478

Q46599371-3730E330-4BAC-47BE-BECD-2F8BC0D99D63

P577

Q46599371-7520BC39-9F13-4647-9724-7A376A0411F5

P5875

Q46599371-E2BDE6F1-C612-40A0-9E06-922E707B0C53

P698

Q46599371-C3211C1F-866C-4579-BF42-282EF32A7CB7

P356

PHYSIOLGENOMICS.00062.2002

P1433

Physiological Genomics

P1476

Angiotensin II is associated w ...... s and downregulation of PPARs.

@en

P2093

Baby Martin-McNulty

http://www.w3.org/2001/XMLSchema#string

Dennis W Wilson

http://www.w3.org/2001/XMLSchema#string

Doris M Tham

http://www.w3.org/2001/XMLSchema#string

John C Rutledge

http://www.w3.org/2001/XMLSchema#string

Mark E Sullivan

http://www.w3.org/2001/XMLSchema#string

Ronald Vergona

http://www.w3.org/2001/XMLSchema#string

William Dole

http://www.w3.org/2001/XMLSchema#string

Yi-xin Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

Function and activation of NF-kappa B in the immune system

Structure, regulation and function of NF-kappa B

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

Atherosclerosis is an inflammatory disease.

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase.

Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor.

Angiotensin II and atherosclerosis.

Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice

P304

21-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/PHYSIOLGENOMICS.00062.2002

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11095881

http://www.w3.org/2001/XMLSchema#string

P698

12361987

http://www.w3.org/2001/XMLSchema#string